Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
The Journal of Antimicrobial Chemotherapy|June 1, 2007
Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind studyThomas M File, Lionel A Mandell, Glenn Tillotson, et al.
BMC Infectious Diseases|April 17, 2015
A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infectionsRichard Vickers, Neil Robinson, Emma Best, et al.
International Journal of Antimicrobial Agents|September 24, 2004
Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002John F Mohr, Annie Jones, Luis Ostrosky-Zeichner, et al.
Open Forum Infectious Diseases|December 18, 2019
Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin or Vancomycin for a Skin Infection in the Outpatient SettingThomas P Lodise, Christina Palazzolo, Kerry Reksc, et al.
American Journal of Infection Control|March 31, 2019
Physicians' attitude and knowledge regarding antibiotic use and resistance in ambulatory settingsAmanda Harris, Suganya Chandramohan, Reda A Awali, et al.
Open Forum Infectious Diseases|April 8, 2022
Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of PropertiesRandall K Hoover, Martin Krsak, Kyle C Molina, et al.
American Journal of Infection Control|January 4, 2024
Gut microbiome alpha diversity decreases in relation to body weight, antibiotic exposure, and infection with multidrug-resistant organismsJonathan J Panzer, Catherine Maples, Monica P Meyer, et al.
Open Forum Infectious Diseases|May 9, 2017
Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical TrialsThomas P Lodise, Mark Redell, Shannon O Armstrong, et al.
Anaerobe|November 29, 2021
The burden of Clostridioides difficile infection in COVID-19 patients: A systematic review and meta-analysisGuido Granata, Nicola Petrosillo, Samir Al Moghazi, et al.
Open Forum Infectious Diseases|January 23, 2023
Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying ComorbiditiesGlenn Tillotson, Laurie Archbald-Pannone, Stuart Johnson, et al.
Pageof 6